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Highlights
• The study demonstrates the safety, feasibility and effectiveness of a comprehensive approach to 
minimize fluoroscopy and contrast use during Watchman left atrial closure device implantation.
Background
The introduction of Watchman left atrial appendage occlusion device (WM) has 
provided an effective alternative to anticoagulation for patients with a high risk 
of cerebrovascular accidents (CVA) and high risk of bleeding and who are unable 
to take long-term anticoagulation therapy. Since its introduction, WM has been 
implanted more than 50,000 times worldwide. While the implant procedure is 
relatively safe, it involves the use of fluoroscopy and contrast and, as such, poses 
some associated risk to patient safety. The adoption of procedural techniques 
which reduce fluoroscopy exposure and contrast use have the potential to provide 
clinical patient benefit without compromising safety or efficacy.
Aim To demonstrate that WM implant can be performed with minimal exposure to both ionizing radiation and IV contrast without compromising safety or efficacy.
Methods
A retrospective chart review of all 75 consecutive Watchman implantations by a 
single operator at a single center between December 2015 and December 2017. 
Every effort to optimize the WM implant procedure and minimize radiation and 
contrast exposure was incorporated as implant techniques evolved. Contrast and 
radiation exposure data were collected and analyzed year-over-year.
Results
Charts from 75 consecutive cases were reviewed with all cases at index procedure 
(100%), and included the majority of patients presenting in paroxysmal AF 
(63%). Baseline patient characteristics were consistent across years. Procedural 
characteristics also were consistent over time. The median absorbed radiation dose 
was low (75 mGy in 2015) and did not change significantly over time. Similarly, 
the median fluoroscopy time used after the initial case was low (2.8 minutes) and 
did not vary. 73 of 75 (97%) of procedures resulted in successful implantation. 
There were no procedural complications; notably, no cases resulted in stroke, 
death, pericardial effusion, vascular accidents or device embolization.
Conclusion
The current generation of WM can be successfully implanted using low fluoroscopy 
and contrast without compromising safety or efficacy using the techniques 
described.
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Introduction
For patients with AF who are at elevated risk of 
thromboembolic CVA, an elevated risk of bleeding and 
a relative contraindication to the use of anticoagulants, 
left atrial occlusion device placement is a proven safe 
and effective alternative to OAC [1, 2]. WM is a novel 
technology which involves the delivery of a LAA 
occlusion device via a transeptal approach and is widely 
in use in the United States and Europe. While standard 
implant techniques have been refined since the early 
clinical trials, device delivery continues to require both 
fluoroscopy and direct injection of IV contrast into the 
left atrium to ensure appropriate positioning and to 
verify appendage occlusion.
Methods
Patients:
This is a retrospective observational study and 
analysis of all 75 consecutive WM implants performed 
by a single operator at a single center from 12/1/15 to 
12/31/17. All patients met local implant criteria and 
provided informed consent. In addition, the majority 
(99%) of patients met the more rigorous Medicare 
implant criteria which included a CHADS2VASC2 rank 
of at least 3 and a HASBLED score of at least [1].
Procedure:
All patients presented for WM implant at our center’s 
EP or hybrid structural heart laboratory. All patients 
were diagnosed with well-documented atrial fibrillation 
and underwent a screening TEE pre-procedure. 
All patients received general anesthesia including 
intubation and underwent TEE probe placement at the 
beginning of the procedure. Intra-procedural TEE was 
used to rule-out left atrial appendage thrombus and to 
guide transeptal puncture and WM delivery. Femoral 
vein access was obtained only under direct ultrasound 
visualization to avoid vascular accidents. In all patients 
a figure-of-eight stitch was placed around femoral vein 
access wires at the beginning of the procedure and 
were used to achieve hemostasis post-procedure and to 
minimize the need for manual pressure during recovery. 
All patients underwent arterial pressure monitoring via 
radial artery sheath placement. All transeptal punctures 
were performed under either TEE guidance or, in a 
minority of patients, using a combination of both TEE 
and intracardiac echocardiography (ICE) guidance. 
ICE was performed using the Zonare ultrasound 
system (Zonare, Mountainview, CA). A single 
transeptal puncture was performed using the Baylis 
radiofrequency needle and ProTrack transeptal spiral 
wire. In those cases where the standard 14 F Boston 
Scientific transeptal sheath could not be easily passed 
through the intra-atrial septum (IAS), a 6 mm x 40 mm 
angioplasty balloon was inflated across the septum to 
pre-dilate. All patients presented on chronic warfarin 
therapy for at least four weeks prior and warfarin was 
not held prior the procedure. In addition, all patients 
received heparin bolus and continuous infusion to 
maintain an activated clotting time (ACT) >300 
seconds prior to the transeptal puncture and until all 
catheters and sheaths were removed from the LA. 73 
patients (97%) underwent successful implant with the 
current generation WM device with sizes ranging from 
21 mm to 33 mm diameter.
Techniques to reduce fluoroscopy and contrast use
Low fluoroscopy exposure and contrast use were 
achieved through several measures:
1. Fluoroscopy system adjustment: fluoroscopy 
exposure can reduced by complying with general 
principles of radiation protection including maximizing 
collimating, optimizing projection angle and reducing 
frame rates. Our standard frame rate is 3.8 frames/
second to start, though this was increased as necessary 
during contrast injections and device deployment as 
necessary to optimize imaging. Most implants were 
performed in a hybrid cardiac catheterization laboratory 
dedicated to structural heart procedures and equipped 
with the newest available fluoroscopy software.
2. Saved images: In addition to using a low frame 
rate, we also used a «single shot» technique where 
individual one-second exposures were performed and 
the static image was saved to a separate review screen 
and used to guide decision-making.
3. Operator preference: perhaps the most critical 
component to reducing fluoroscopy exposure is 
operator awareness, motivation and diligence. In our 
experience, physicians agree to monitor their use and 
actively «stay off the pedal» when they realize that 
fluoroscopy is best used in combination with over other 
forms of imaging (TEE in this case) and not as the sole 
form of direct visualization.
4. Contrast minimization during appendage 
cannulation and catheter positioning: we were able to 
reduce contrast use by administering small (1–2 cc) 
injections with initial cannulation of the appendage 
and to confirm distal appendage positioning of the 
diagnostic pig-tail catheter. We then performed as 
few longer contrast injections as were necessary to 
adequately visualize the distal appendage anatomy and 
os (for sizing and to determine a «landing zone» for 
the device).
5. Contrast injection during deployment: from 
the moment deployment is started, small (1–2 cc) 
injections were performed at short intervals until the 
device was released.
For this study fluoroscopy and contrast use 
reduction were seen in the context of an overall «safety 
first» approach to this procedure. Additional safety 
steps were taken to reduce the risk of complication 
including:
• The use of US guidance and micro-puncture 
kits to access peripheral vessels which minimizes the 
risk of trauma and effectively eliminates the risk of
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 inadvertently puncture of the adjacent artery.
• The use of an RF transeptal needle, atraumatic 
spiral transeptal wire and (when necessary) a dilating 
balloon to insure safe and efficient delivery sheath 
placement.
• Placement of an arterial blood pressure 
monitoring line to allow for beat-to-beat monitoring of 
hemodynamics parameters changes and early detection 
of pericardial effusion.
• The maintenance of an ACT of at least 300 seconds 
prior to the TSP to minimize the risk of CVA due to LA 
thromboembolism.
• The use of a figure-of-eight groin closure stitch 
and an adjustable suture tension device to reducing the 
risk of hematoma and obviate the need for protamine 
post procedure.
• Limited transthoracic echocardiogram performed 
within two to 12 hours post-procedure to document any 
post-procedure pericardial effusion.
Post implant care:
All venous sheaths were removed in the EP lab 
immediately post-procedure irrespective of ACT or 
INR levels. Hemostasis in the femoral veins was 
achieved using a «figure of eight» stitch and suture 
retention device. The arterial monitoring sheath was 
removed routinely post procedure when the ACT was 
under 200 seconds. Protamine was not administered. 
All patients received a post-procedure transthoracic 
echocardiogram to confirm the absence of pericardial 
effusion between one and 12 hours after implant. All 
patients recovered in our post-anesthesia care unit 
before being transferred to our telemetry unit overnight 
and were discharged the following day if they met 
discharge criteria. All patients remained on warfarin 
and aspirin post-procedure for 6 weeks before switching 
to aspirin and clopidogrel for an additional 18 weeks, 
following which all patients were maintained on aspirin 
only. The 6-week post-implant TEE demonstrated no 
thrombus or peri-device flow >6 mm in diameter and 
no device embolization in all patients.
Data collection and statistical analysis:
Statistics are reported for each WM case. 
Baseline characteristics for all patients are presented. 
Frequencies and percentages were displayed for 
categorical variables. Continuous variables were 
analyzed as median with interquartile range, unless 
otherwise stated. Descriptive statistics were calculated 
in total and by procedure year: 2015, 2016, 2017.
Tools
The primary tools for the statistical analysis were 
Excel (Microsoft Excel 2016 with the QI Macros 2015 
add-in) and RStudio (RStudio v3.4.4 with the ggplot2 
package, accessed via RStudio.cloud).
Analysis ‒ Statistical
The data were cleaned and statistically analyzed 
using Excel. There was only one observation from 
2015, so, for the purposes of analysis, that observation 
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was removed from the data set during hypothesis 
testing.
For the descriptive statistics, the median was 
selected due to several of the variables exhibiting non-
normality. For consistency, median was the preferred 
method for determining central tendency throughout 
the analysis. When calculating the interquartile ranges, 
the Excel function QUARTILE.EXC was employed.
Hypothesis testing used nonparametric approaches. 
Continuous-variable data were analyzed using the 
Mann-Whitney U test. For each such variable, the 
observations were stratified into two groups by year 
(2016 and 2017). In each case, the null hypothesis was 
that the two distributions were equal.
Attribute data were analyzed using the 2 Proportions 
test. For each such variable, the observations were 
stratified into two groups by year (2016 and 2017). In 
each case, the null hypothesis was that the difference 
between the two proportions was zero.
Analysis ‒ Graphical
Several variables were analyzed graphically using 
box plots, created in RStudio. In one case (Fluoroscopy 
Time for 2016), one observation (326 minutes, 
observation ID 12) was removed. The removal of this 
outlier did not change the median value (2.8 minutes).
Results
Baseline characteristics:
Between 2015 and 2017, data from 75 procedures 
were collected retrospectively and presented in Table 
1. 73 of 75 patients underwent successful implant. 
Both patients with failed implant underwent multiple 
attempts with multiple devices but, due to challenging 
anatomy and concern for patient safety, the procedures 
were terminated without successful implant. Patients 
were a median age of 76 years old and 54.6% male. 
Patient characteristics were generally consistent across 
the duration of the study; no differences reached 
statistical significance (alpha = 0.05 throughout 
this study). The CHADS2VASc score remained 
high (median 4) reflecting multiple risk factors for 
thromboembolic events. Most patients presented with 
paroxysmal AF 62.7% (table 2). Notably, there is 
no difference in measures of patient size, which can 
impact radiation absorbed dose, across procedure years 
(median body surface area 1.99 m2, median body mass 
index 30.02 kg/m2).
Procedural characteristics are shown in table 3:
1. Procedure time: remained within an expected 
range at a median of 55 minutes and remained relatively 
constant.
2. Device size: device sizes ranged from 21 mm to 
33 mm and the distribution did not change significantly 
over time.
3. Number of device recaptures: The number of 
device recaptures reflected the complexity of the cases: 
the more recaptures (partial or full) reflected more
challenging anatomy. 32% of cases required at least 
one partial recapture while 24% of cases required at 
least one full recapture.
4. Radiation exposure and contrast use: Median 
fluoroscopy time after the first case in 2015 was low 
(2.8 minutes) and remained low over time. Median 
absorbed dose (mGy), a more relevant measure of 
radiation exposure, was low (median 193 mGy) and, 
while it increased over time, the change was not 
statistically significant.
Complications:
There were no procedural complications.
Procedural success:
Procedural success was defined as successful 
implant of WMN device which met all PASS criteria: 
appropriate Position, sufficient Anchor, correct 
Size (compression between 8 and 20%), evidence 
of adequate Seal (no peri-device leak of >5mm). 
Implantation was aborted in 2 (2.7%) patients due to 
inability to confirm all four PASS criteria after multiple 
attempts and multiple devices.
Discussion
As the number and types of invasive cardiac 
catheterization laboratory procedures continues to 
grow worldwide each year, so has the concern for the 
use of procedure-related fluoroscopy. This is due to 
the understanding that fluoroscopy requires the use 
of ionizing radiation, that fluoroscopy continues to be 
the sole or primary imaging mode for such procedures 
and that patients who are increasingly likely to need 
multiple radiation-based procedures over their lifetimes.
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Note: Baseline characteristics. An «n/a» entry means not applicable, since there was only one observation. Where performed, 
hypothesis testing compares the observations from 2016 with the observations from 2017.
Attribute Statistic All observations 2015 2016 2017
p
value Hypothesis Test
Age 
count 75 1 33 41
median 76 63 76 77 0.22 Mann-Whitney
interquartile range 9 n/a 10 8
Gender % who are male 54.67% 100.00% 57.58% 51.22% 0.58 2 Proportions
Height (cm) 
median 170 185 170 168 0.39 Mann-Whitney
interquartile range 14.0 n/a 12.5 14.5
Weight (kg)
median 85.1 106.1 84.6 81.7 0.18 Mann-Whitney
interquartile range 32.4 n/a 40.7 29.8
Last BSA (m2) 
median 1.99 2.32 1.99 1.96 0.23 Mann-Whitney
interquartile range 0.37 n/a 0.46 0.36
Last BMI (kg/m2) 
median 30.02 31.39 29.92 30.19 0.37 Mann-Whitney
interquartile range 10.26 n/a 12.53 7.87
CHADS-VASc 
Score
median 4 2 4 4 0.17 Mann-Whitney
interquartile range 2 n/a 2 1
CHF % with CHF 16.00% 0.00% 24.24% 9.76% 0.10 2 Proportions
LVEF
median 60 60 60 60 0.23 Mann-Whitney
interquartile range 11.0 n/a 9.5 10.0
Obstructive sleep 
apnea % with OSA 20.00% 0.00% 15.15% 24.39% 0.31 2 Proportions
Diabetes % with Diabetes 38.67% 100.00% 45.45% 31.71% 0.22 2 Proportions
Table 2. Atrial fibrillation type distribution
Note: Case mix by year. 
All observations 2015 2016 2017
Paroxysmal atrial fibrillation % of cases 62.67% 100.00% 45.45% 75.61%
Persistent atrial fibrillation % of cases 21.33% 0.00% 36.36% 9.76%
Permanent atrial fibrillation % of cases 16.00% 0.00% 18.18% 14.63%
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In addition, it is well understood that there is no 
safe level of radiation exposure [3]. The hypothesis 
regarding the harmful effects of low-dose exposure is 
extrapolated from the known effects of radiation at high 
doses, referred to as the «linear non-threshold model» 
which accepts that risk is related to the cumulative 
exposure over time. Fortunately, multiple published 
studies have demonstrated the feasibility, efficacy and 
safety of minimizing or eliminating fluoroscopy during 
electrophysiology studies and the techniques which 
reduce fluoroscopy use appear to be transferable to 
other interventional procedures, including WM [4‒8].
It is well documented that WM is a safe and effective 
alternative to OAC in patients with AF and high risk of 
CVA and bleeding who also have a contraindication to 
long-term use of OAC [1, 2]. While implant is relatively 
safe, it requires the use of a combination of fluoroscopy 
and intra-atrial contrast injections under TEE guidance 
[9, 10] with the in associated risks. In spite of attempts 
to find alternatives to fluoroscopy and contrast use 
(including reported cases of successful device delivery 
under ICE guidance), implant techniques have not 
changed significantly since the device received FDA 
approval for widespread use in the United States in 
2015. Until now there are no published studies that 
have evaluated a systematic approach to reducing 
fluoroscopy and contrast use during implant.
Over the course of the first 75 implants at our 
center by a single operator from December, 2015 to 
December, 2017 a conscientious effort was made to 
minimize fluoroscopy and contrast use by employing 
a variety of techniques and safe practices originally 
developed for other invasive EP procedures. These 
data demonstrate that taking such an approach does 
not increase procedure time beyond what would be 
expected or result increased complications and does 
not require additional equipment or operator training 
beyond what is currently recommended. While this 
study did not demonstrate a significant reduction in 
radiation exposure and contrast use over time, median 
levels started and remained low across time. While 
median radiation exposure dose did appear to increase 
over time, this was not statistically significant. Of note, 
while no direct cause of increased radiation exposure 
time is obvious from the data, it appears to be due 
at least in part to the complexity of the cases which 
appeared to increase in 2017 as we attempted more 
challenging anatomy. These data reflect a conscientious 
effort by the operator to ensure patient safety.
Study limitations and future perspective
This study represents a retrospective observational 
study by a single operator at a single center; 
interpretations are limited due to the nature of the 
data. Additionally, the operator is a relatively high-
volume WM implanter who also performs over 100 
additional transeptal EP procedures annually and has 
performed over 500 transeptal procedures in the last 7 
years. However, as demonstrated here, achieving these 
results involved no particular skill set which could not 
be easily developed by any experienced operator.
This study is also limited by the fact that a comparison
Table 3. Procedural characteristics
Note: Procedural data. An «n/a» entry means not applicable, since there was only one observation. Where performed, hypothesis 
testing compares the observations from 2016 with the observations from 2017.
Attribute Statistic All observations 2015 2016 2017
p
value Hypothesis Test
Successful implant % successful 97.33% 100.00% 100.00% 95.12% 0.15 2 Proportions
Device size (mm) 
median 24 24 24 24 0.99 Mann-Whitney
interquartile range 3 n/a 3 3
Preimplant Os size 
(mm)
median 20 17 20 21 0.49 Mann-Whitney
interquartile range 5 n/a 4 5
Fluoroscopy 
exposure dose 
(mGy)
median 193 75 165 225 0.15 Mann-Whitney
interquartile range 280 n/a 243 285
Fluoroscopy time 
(min) 
median 2.8 7.5 2.8 2.8 0.87 Mann-Whitney
interquartile range 2.0 n/a 2.3 1.5
Contrast volume (cc)
median 70 65 70 70 0.40 Mann-Whitney
interquartile range 50.0 n/a 58.0 50.5
Procedure time 
(mins)
median 55 59 55 52 0.07 Mann-Whitney
interquartile range 19.0 n/a 24.5 18.5
Partial recaptures % of cases 32.00% 100.00% 30.30% 31.71% 0.90 2 Proportions
Full recaptures % of cases 24.00% 0.00% 18.18% 29.27% 0.26 2 Proportions
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cannot be made with prior WM data on fluoroscopy 
and contrast use, as this was not reported in any of the 
published papers.
Possible future directions include the use of ICE 
to effectively visualize the LAA, obviating the need 
for simultaneous TEE. To date, two studies have 
demonstrated its safety and efficacy in comparison 
to current implant methods but wide-spread adoption 
appears to be limited by several factors, including cost 
[8, 9]. Finally, the latest generation device, Watchman 
FLX, holds promise for easier implants due to the 
limited LAA depth required to deploy the device and 
greater flexibility in capturing and repositioning.
Conclusion
This retrospective, observational study demonstrates 
the safety, feasibility and effectiveness of a 
comprehensive approach to minimize fluoroscopy and 
contrast use during WM implants without compromising 
safety. While neither contrast nor fluoroscopy use 
decreased over time, both started and remained low. 
There were no complications associated with this study.
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